Pfizer Inc.saw its biosimilars segment jump 80% in operational growth and 79% as reported in the third quarter of 2020, clocking sales of $424m compared to $236m recorded in the prior-year period.
While Pfizer’s US biosimilars reported revenues of $260m, developed Europe earned $122m, the developed rest of the world region generated...





